Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $11.15 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.